

Drug Utilization Review (DUR) Meeting Minutes
March 11, 2013

Members Present: Norman Byers, John Savageau, Leann Ness, David Clinkenbeard, Carrie Sorenson, Cheryl Huber, Carlotta McCleary, Greg Pfister, Michael Booth, Jeffrey Hostetter

Members Absent: Steve Irsfeld, Todd Twogood, Russ Sobotta, Tanya Schmidt, James Carlson

Medicaid Pharmacy Department: Brendan Joyce, Gary Betting

HID Staff Present: Candace Rieth

Chair G. Pfister called the meeting to order at 1:00 pm. Chair G. Pfister asked for a motion to approve the minutes from the December meeting. N. Byers moved that the minutes be approved, and C. Huber seconded the motion. Chair G. Pfister called for a voice vote to approve the minutes. The motion passed with no audible dissent.

Budget Update

B. Joyce informed the board members that there is no new information since the last board meeting.

Genitourinary Smooth Muscle Relaxants (GSM) Second Review

A motion and second were made at the December meeting to place Genitourinary Smooth Muscle Relaxants on prior authorization. The topic was brought up for a second review. There was no public comment. After discussion, Chair G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

Multiple Sclerosis Second Review

A motion and second were made at the December meeting to place agents used to treat multiple sclerosis (i.e., Aubagio) on prior authorization. The topic was brought up for a second review. Susan Grindle, representing Teva, spoke regarding Copaxone. Chair G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

Update on Medications Greater than \$3,000

B. Joyce reviewed medications that cost greater than \$3,000. Recently, three specialty medications came to market that prompted a closer review of high dollar agents. Utilization and new medication to market information was provided to the Board. B. Joyce informed the Board that the State is being vigilant to add these drugs to the PA list as soon as they come on the market. This not only ensures appropriate use, but also cost management when appropriate.

Fulyzaq Review

B. Joyce reviewed Fulyzaq clinical information with the board. There was no public comment. J. Hostetter made a motion to place Fulyzaq on prior authorization. C. Sorenson seconded the motion. This topic will be brought up at the next meeting for finalization.

Xeljanz Review

B. Joyce reviewed Xeljanz clinical information with the board. T. Hartman, representing Pfizer, spoke regarding Xeljanz. J. Hostetter made a motion to place Xeljanz on prior authorization. G. Pfister seconded the motion. This topic will be brought up at the next meeting for finalization.

Asthma Management

Wendy Brown, Associate Professor at the NDSU College of Pharmacy and Clinical Coordinator of About the Patient, spoke regarding asthma management in the ND Medicaid population. About the Patient is currently writing a grant proposal to develop a Medication Therapy Management (MTM) program for ND Medicaid recipients, designed to help build collaboration between prescribing health professionals, pharmacists, and patients with asthma in order to optimize medication use and disease control.

Criteria Recommendations

The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and usually are consistent with new indications, new drugs added, new warnings, etc. These proposed criteria will be added to the current set of criteria and will be used in future DUR cycles. C. Huber moved to approve the new criteria and G. Pfister seconded the motion. Chair G. Pfister called for a voice vote. The motion passed with no audible dissent.

The next DUR board meeting will be held June 3, 2013, in Bismarck. C. Sorenson made a motion to adjourn the meeting. J. Hostetter seconded. The motion passed with no audible dissent. G. Pfister adjourned the meeting.